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Background. In malaria-endemic areas it is recommended that febrile children be tested for malaria by rapid
diagnostic test (RDT) or blood slide (BS) and receive effective malaria treatment only if results are positive.
However, RDTs are known to perform less well for Plasmodium vivax. We evaluated the safety of withholding
antimalarial drugs from young Papua New Guinean children with negative RDT results in areas with high levels of
both Plasmodium falciparum and P. vivax infections.
Methods. longitudinal prospective study of children aged 3–27 months visiting outpatient clinics for fever. RDT
was administered at first visit. RDT and microscopy were performed if children returned because of persistent
symptoms. Outcomes were rates of reattendance and occurrence of severe illnesses.
Results. Of 5670 febrile episodes, 3942 (70%) involved a negative RDT result. In 133 cases (3.4%), the children
reattended the clinic within 7 days for fever, of whom 29 (0.7%) were parasitemic by RDT or microscopy. Of
children who reattended, 24 (0.7%) presented with a severe illness: 2 had lower respiratory tract infections (LRTIs)
with low-density P. vivax on BS; 2 received a diagnosis of P. vivax malaria on the basis of RDT but BSs were negative;
16 had LRTIs; 3 had alternative diagnoses. Of these 24, 22 were cured at day 28. Two children died of illnesses other
than malaria and were RDT and BS negative at the initial and subsequent visits.
Conclusion. Treatment for malaria based on RDT results is safe and feasible even in infants living in areas with
moderate to high endemicity for both P. falciparum and P. vivax infections.
In many countries, patients are treated presumptively for
malaria when presenting with febrile illnesses. This is
because (1) no diagnostic tools are available (microscopy
or rapid diagnostic tests), (2) health workers do not trust
the results of these tests [1, 2], or (3) there are scarce data
on the safety of withholding antimalarial drugs in patients
with a negative malaria test result. This is especially true in
children aged ,5 years, for whom presumptive antima-
larial treatment was promoted by the World Health Or-
ganization (WHO) [3] for decades before a change of
policy toward universal diagnosis beginning in 2010 [4].
The situation has evolved, and more tools and data are
now available for the management of suspected malaria
episodes, in particular in sub-Saharan Africa [5]. First,
community awareness in endemic areas of the impor-
tance of early attendance at a health facility when a child is
febrile has improved [6]. Second, reliable and affordable
rapid diagnostic tests (RDTs) for malaria are now widely
available [7, 8, 9, 10]. Third, safe and highly efficacious
treatments for malaria (artemisinin-based combination
therapies) are available in almost all endemic countries.
Last, 2 recently published studies have demonstrated
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the safety of withholding antimalarial drugs in children aged
,5 years and adults with negative malaria RDT results in
Tanzania, where Plasmodium falciparum is the predominant
species [11, 12].
The safety and effectiveness of microscopy or RDT-based
malaria treatment have not been investigated in infants. More-
over, it is not clear whether withholding antimalarial treatment in
young children with fever and negative RDT results is safe in
different epidemiological contexts, especially in areas with a high
prevalence of Plasmodium vivax infections. This is a concern,
because it is now well established that untreated P. vivax infections
might lead to severe diseases [13, 14]. Part of the uncertainty lies
in the fact that many RDTs are less sensitive for the diagnosis of
P. vivax infections than for P. falciparum [8, 15, 16, 17]. More data
are thus needed to ensure that the new WHO policy of prescribing
antimalarials only to children with confirmed parasitemia is safe
in all settings [18]. It must be a priority in terms of clinical
management of febrile illnesses, because it is well recognized that
presumptive treatment for malaria may delay the management of
other potentially life-threatening diseases and promote the de-
velopment of resistance to antimalarial drugs [1].
In coastal Papua New Guinea, malaria is highly endemic and
P. vivax accounts for at least one-half of all infections in children
aged,5 years [19, 20, 21]. As part of a large trial of intermittent
preventive treatment in infants (IPTi) (Senn N et al, submitted,
September 2011), a passive case detection surveillance system
was implemented. All sick study participants presenting spon-
taneously at the study clinics with fever or history of fever were
screened with an RDT for P. falciparum and non–P. falciparum
malaria infections and treated with artemether-lumefantrine
only when the test was positive for one or the other species. The
standardized approach to case management used thus offered an
excellent opportunity to investigate the safety of withholding
antimalarial drugs in febrile patients with a negative RDT result
in a situation where P. vivax infections are very common.
METHODS
Background and Study Sites
This work was carried out alongside an IPTi trial that included
1605 children aged 3 months old at enrollement and followed-up
until 27 months between 2006 and 2010 (www.ClinicalTrials.gov:
NCT00285662). Children were randomly assigned to a treatment
course of a single dose of sulfadoxine/pyrimethamine (SP) with
either 3 days of amodiaquine (SP-3AQ) or 3 days of artesunate
(SP-3AT), or to a placebo group. The doses were given every
3 months during the first year of life, along the immunization
schedule.
This trial took place in 2 locations: (1) Mugil (Madang
province): the main study site where an average of 0.94 epi-
sodes per child per year was observed and P. vivax accounted
for more than two-thirds of all infections; and (2) Maprik (East
Sepik province): a secondary study site where the incidence of
malaria was significantly lower (0.13 episodes per child per
year; P , .001).
Data Collection
A passive case detection surveillance system had been established
for 16 years in Maprik [14] and 3 years in Mugil [22] prior to
the present study. The same infrastructure was used for IPTi.
A standard case report form was completed for each illness
episode that included all relevant signs and symptoms, as well
as the clinical management. When presenting with fever/history
of fever during the past 48 hours, children were screened with
an RDT for P. falciparum and non–P. falciparum malaria
infections (ICT Combo, South Africa) and treated with
Table 1. Matrix of Interpretation of Blood Slides and Rapid Diagnostic Test Results Upon Reattendance at Clinic
RDT Results
BS Results Neg Pf Pv Possibly Mixed Pf and Pv No RDT
Neg Def nega Poss Pfb Poss Pvb Poss Pf and poss Pvb Prob nega
Pf Prob Pfc Def Pfd Prob Pf and poss Pvd Def Pf and poss Pvd Prob Pfc
Pv Prob Pvc Prob Pv and poss Pfd Def Pvd Def Pv and poss Pfd Prob Pvc
Pm Prob Pmc Prob Pm and poss Pfd Def Pmd Def Pm and poss Pfd Prob Pmc
Mix Prob Pf and prob Pvc Def Pf and prob Pvd Def Pv and prob Pfd Def Pf and def Pvd Prob Pf and prob Pvc
No BS Poss nega Poss Pfb Poss Pvb Poss Pf and poss Pvb No resultse
Abbreviations: BS, blood slide; Def, definite; neg, negative; Pf, Plasmodium falciparum; Pm, Plasmodium malariae; poss, possible; prob, probable; Pv, Plasmodium
vivax; RDT, rapid diagnostic test.
a Negative malaria.
b Possible malaria.
c Probable malaria.
d Definite malaria.
e No results.
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artemether-lumefantrine (Coartem, Novartis) only if the test
result was positive for any species.
Two thick and thin blood slides (BSs) for malaria microscopy
were also collected. On the rare occasions when infants visited
a health facility after hours (when the study clinics were closed),
they were managed according to the national guidelines by the
staff on duty. A review was made by study nurses on the following
day. If a child died at home, a verbal autopsy was performed
(assessing the possible cause of death on the basis of information
provided by parents through a standardized questionnaire).
All procedures followed the Good Clinical Practice guidelines,
and all parents signed an informed consent form when enrolling
their child in the IPTi study. The IPTi protocol was approved by
the Medical Research Advisory Committee of Papua New
Guinea (MRAC no. 05/20).
Study Design and Procedures
The present work makes use of morbidity data of the IPTi trial
cohort to perform a safety assessment of children for whom an
RDT was performed as part of a passive case detection visit. The
inclusion criteria were as follows: RDT performed, children aged
3–27 months enrolled in the IPTi study, history of fever during the
previous 48 hours and/or temperature.37.5C, no positive RDT
result during the previous 4 weeks, no consultation for history of
fever/elevated temperature during the past 2 weeks, no antima-
larial drugs prescribed on the day of consultation if RDT negative,
and no severe illness on the day of consultation. One or more
illness episodes could occur for each child enrolled in the study.
For all children with the above-mentioned inclusion criteria,
we determined whether they reattended any of the study clinics
during the following 7 and 28 days. Upon reattendance, we in-
vestigated whether they still had fever and examined the clinical
and laboratory outcomes. Each child’s reattendance was classified
as death, severe illness, or nonsevere illness managed as an am-
bulatory case. The result of the new RDT performed upon re-
attendance was confirmed by BS for all illness episodes and
deaths. For the children who had died or had been admitted
elsewhere or after hours, we recorded the diagnosis, management,
Figure 1. A and B, Flowcharts showing the clinical and parasitological outcomes upon reattendance within 7 and 28 days following a negative rapid
diagnostic test (RDT) result. Abbreviations: Pf, Plasmodium falciparum; Pv, Plasmodium vivax.
646 d CID 2012:54 (1 March) d Senn et al
and treatment from the health book or records from the health
center. A severe illness was defined as an illness episode that
resulted in hospital admission or was life-threatening (see Sup-
plementary Table 1 for criteria).
Interpretation of Blood Slide and RDT Results
Study participants who experienced a febrile episode underwent
RDT so that a course of treatment could be determined. A BS was
also collected for research purposes but was read months
after the episode. Thick films were examined by light mi-
croscopy for 200 fields before being declared infection neg-
ative. Parasite species in positive films were identified and
densities recorded as the number of parasites per 200 white
blood cells (WBCs). Densities were converted to the number
of parasites per microliter of blood assuming 8000 WBCs
per lL (population average WBC count [3]). All slides were
read independently by 2 experienced microscopists, and in
cases of discrepant readings a third independent reading was
performed.
It is well known that discrepancies between BS readings and
RDT results can be important because of the fact that the 2 tests
detect different components (antigens for RDT and whole
parasites for microscopy). Therefore, we designed a matrix to
interpret the combination of BS and RDT upon reattendance
using conservative criteria to define malaria (see Table 1). Ac-
cording to this matrix, we defined 4 categories of malaria status
upon reattendance: (1) negative 5 BS negative and RDT neg-
ative, or BS or RDT negative and corresponding BS or RDT
absent; (2) definite malaria 5 BS positive and RDT positive;
(3) probable malaria5 BS positive and RDT negative or absent;
(4) possible malaria 5 RDT positive and BS negative or absent.
Data Analysis
Data were double-entered using FoxPro software. Data manage-
ment and analyses were performed using STATA software, version
10.0 (StataCorp). Reattendance rates within 7 and 28 days for the
different outcomes were obtained for children fulfilling inclusion
criteria.
Figure 1. Continued.
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RESULTS
General Description of the Cohort
Between June 2006 and May 2010, 1605 children aged
3–27 months were enrolled and followed up in the IPTi ran-
domized controlled trial (Madang, 1125; Maprik, 480). A total
of 1512 children (94%) experienced at least 1 illness episode
(Madang, 1053; Maprik, 459). The morbidity surveillance
reported a total of 8944 illness episodes (Madang, 5978;
Maprik, 2966), of which 7223 were febrile (Madang, 5249;
Maprik, 1974). The average number of febrile episodes per
child was 4.8. Thirteen deaths and 371 severe illnesses were
reported during the observation period. The mean duration of
symptoms before attendance was 2.7 days (95% confidence
interval [CI], 2.6–2.8 days) in febrile children.
A total of 5670 febrile episodes (Madang, 4103; Maprik, 1567)
fulfilled the inclusion criteria and were included in the analysis;
1899 occurred in children enrolled in the SP-3AQ group, 1888 in
the SP-3AT group, and 1883 in the placebo group. A total of
3942 (70%) of the episodes occurred in infants who had a neg-
ative RDT result at inclusion; 2512 (61% [95% CI, 60%–63%])
were negative in Madang (high endemicity) and 1430 (91% [95%
CI, 90%–93%]) in Maprik (low endemicity). There was a positive
RDT result at inclusion for 1728 (30% [95% CI, 29%–32%])
febrile episodes. According to RDT results, 19% (95% CI,
17%–21%) were positive for P. falciparum only, 37% (95% CI,
35%–39%) were possibly mixed infections (P. falciparum single or
mixed with P. vivax, Plasmodium ovale, or Plasmodium malariae),
and 44% (95% CI, 42%–46%) were non–P. falciparum infections.
The median duration of symptoms was similar for children with
negative and positive RDT results (2 days [interquartile ranges
{IQRs} of 1–3 and 1–4, respectively]).
Clinical and Parasitological Outcomes Upon Reattendance
Within 7 and 28 Days Following a Negative RDT Result
Figure 1A displays the outcome within 7 days of febrile episodes
for children with a negative RDT result. Among the 3942 febrile
episodes associated with a negative RDT result, 172 (4.4%) oc-
curred in children who reattended the clinic within 7 days, of
whom 133 (3.4%) had a history of fever and/or temperature
.37.5C. Twenty-nine (0.7%) of 3942 children with negative
RDT result at day 0 reattended the clinic with a parasitemia
identified by means of RDT and/or BS. Among the 133 children
who reattended with fever, 24 children (0.7%) presented with
a severe illness, the median duration between initial negative RDT
result and severe illness being 2 days (IQR, 1–4 days). Table 2
describes these severe illnesses in detail. Six children with a severe
illness had neither an RDT nor a BS performed. This was usually
because they were admitted during the night at the health facility
when no study staff were present. For these children, the likely
diagnosis was made on the basis of clinical records matched with
treatment records. Of the 24 patients reattending with a severe
illness, 2 children died, one upon admission of probable severe
respiratory infection (as per clinical assessment), the other a week
after admission probably of meningitis while being treated for
a lower tract respiratory infection (LRTI); for both children RDT
and BS were negative at initial and subsequent visit(s). Among the
other 22 patients, 2 infants merited antimalarial treatment, be-
cause they received a clinical diagnosis of LRTI simultaneous with
low-density P. vivax parasitemia (,1000 parasites/lL), but nei-
ther received treatment. Two other children had an RDT positive
for P. vivax with negative BS result.
Considering the cumulative reattendance pattern from 0 to
28 days (Figure 1B), 725 infants visited the clinic, 573 had fever,
48 had a severe illness, and 2 died within 7 days (those already
described above). For the 48 severe illnesses, up to 3 different
diagnoses per child were recorded. The recorded clinical diag-
noses included 32 LRTIs, 10 malaria infections (according to BS
and/or RDT results: 3 definite malaria, 5 possible, and 2 negative;
detailed species results are displayed in Figure 1B), 8 neurological
syndromes (febrile fits and/or meningitis), 4 gastrointestinal
diseases, 5 cases of anemia, 2 cases of otitis, 2 upper respiratory
tract infections, 1 skin infection, and 5 other diagnoses.
DISCUSSION
In this study, we show that managing febrile infants with anti-
malarials solely on the basis of results of RDT was safe and
effective in areas with a high endemicity for both P. falciparum
and P. vivax in Papua New Guinea. These findings provide solid
evidence of the safety of withholding antimalarial drugs in infants
in an area highly endemic for P. vivax on the basis of the results of
RDT only. They also confirm those of 2 other studies performed
in older children and adults in Africa where P. falciparum was the
predominant species [11, 12].
Although this study was conducted alongside a randomized
controlled trial, no active follow-up of study participants was
performed. Such passive case detection may reflect health-seeking
behavior in routine practice in a location such as Papua New
Guinea.
Almost 6000 febrile episodes were included in our analysis,
and one-third of them were associated with malaria parasitemia
according to the RDT results. No child died or had a severe
illness because he/she was not treated with an antimalarial drug
when the RDT result was negative. Among the patients with
a negative RDT result, ,4% reattended one of the study clinics
within 7 days with persistent fever and only 0.7% (24) presented
with a severe illness. About 0.1% of children with an initial
negative RDT result reattended within 7 days with parasitemia
identified by RDT or BS (none had definite malaria on the basis
of a positive RDT result and BS). This represents the most
conservative estimate of possibly missed malaria cases. Indeed,
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this includes not only recrudescence and relapses, but also new
infections, coincidental parasitemia (most of them had a clear
alternative diagnosis), and persisting antigenemia detected by
means of RDT. Two children were admitted with a possibly
missed diagnosis of malaria 1 day after the initial visit (2 with low-
density P. vivax on BS, 1 with RDT-negative result and 1 without
RDT result). These 2 severe illness episodes were treated appro-
priately, and the patients recovered without sequelae. It is however
not possible to tell whether these cases were truly missed, or if they
involved a new occurrence of malaria, or whether it was coinci-
dental infection not responsible for the febrile episode.
These data are especially reassuring, because the RDTs used
are known to have a limited sensitivity for the detection of low-
density P. vivax infections. Indeed, as shown in the WHO’s
report on the performances of RDTs (round 2), the test used
(ICT Combo) performed well at high densities of P. vivax
(2000 parasites/lL) with a detection score of .90%, but poorly
with 200 parasites/lL (detection score close to 0%) [8, 23]. The
sensitivity of BS is greatly dependent on an individual micro-
scopist’s skills. Although highly trained and experienced mi-
croscopists, such as those who participated in this study, are able
to readily identify parasitemia at concentrations of as low as
40 parasites/lL, the sensitivity of routine field microscopy is often
substantially lower [24] and may not be superior to RDT-based
diagnosis [25]. Nevertheless, this study highlights that appropriate
use of even an imperfect tool can result in a very high overall
clinical effectiveness. Because a new generation of tests with sen-
sitivities for P. vivax as high as those for P. falciparum [26] are now
available, the effectiveness of RDT-based diagnosis and treatment
should increase even further.
This good clinical performance of RDTs calls into question
the benefits of using more sensitive diagnostic tools, such as
Table 2. Details of Severe Illnesses at Reattendance Within 7 Days After a Negative Rapid Diagnostic Test for Malaria
Case
No.
RDTm at
Reattendance
Blood Slide
at Reattendance
Antibiotics
Receiveda
Antimalarial
Received
Likely
Diagnosisb Outcome Comments
1 Neg Neg Yes No LRTI Died Died on day
of reattendance
2 Neg Neg Yes No LRTI Died Died 7 days
later of meningitis
3 Neg Neg Yes No LRTI Cured
4 Neg Neg Yes No LRTI Cured
5 Neg Neg Yes No Malnutrition 1 LRTI Cured
6 Neg Neg Yes No LRTI Cured
7 Neg Neg Yes No Gastroenteritis Cured
8 Neg Neg Yes No LRTI 1 febrile fits Cured
9 Neg Neg Yes No LRTI Cured
10 Neg Neg Yes No LRTI Cured
11 Neg Neg Yes No LRTI Cured
12 Neg Neg Yes No LRTI Cured
13 Neg Neg Yes No LRTI Cured
14 Pos Neg No Yes LRTI Cured
15 Pos Neg Yes Yes LRTI 1 gastroenteritis Cured
16 Not done Neg Yes Yes LRTI Cured
17 Neg Pos (Pv 960/lL) Yes No LRTI 1 anemia 1
parasitemia (Pv)
Cured Received
co-trimoxazole
18 Not done Pos (Pv 360/lL) Yes No LRTI 1 parasitemia (Pv) Cured
19 Not done Not done Yes Yes Skin abscess
at injection site
Cured
20 Not done Not done Yes No LRTI 1 febrile fits Cured
21 Not done Not done Yes No LRTI Cured
22 Not done Not done Yes No LRTI Cured
23 Not done Not done Yes No Tuberculosis Cured Received
antituberculosis
treatment
24 Not done Not done Yes No LRTI Cured
Abbreviations: LRTI, lower respiratory tract infection; neg, negative; pos, positive; Pv, Plasmodium vivax; RDTm, rapid diagnostic test for malaria.
a Received penicillin or erythromycin unless specified in the comment column.
b Likely diagnosis is based on the review of clinical records matched with RDTm and blood slide results and the treatment received.
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polymerase chain reaction (PCR), for the management of clin-
ical cases in rural health centers. Although PCR may be useful to
confirm the species or to identify cryptic infections in non-
immune patients, it requires substantial resources and, even if
point-of-care PCR systems become available, is unlikely to be
cost-effective in most settings.
Previous studies in Africa showed that clinicians did not al-
ways treat children on the basis of malaria test results and tended
to give antimalarials even to children with negative results [1, 27].
More recent pilot programs of RDT implementation in Zanzibar
and Tanzania showed an excellent adherence to a policy of
prescription based on positive test results. This strategy led to
a dramatic reduction in consumption of antimalarial agents
[12, 28, 29, 30]. One of the main contributors to the success of
the most recent studies was a comprehensive training program,
which led to a true change in clinicians’ behavior. Unfortunately,
the guidelines for management of nonmalaria fever episodes are
often based only on syndromic management. On the basis of the
experience with malaria and RDT, there is thus a need to develop
new strategies that include easy-to-use tools able to investigate
objectively the etiologies of nonmalaria fever episodes, especially
in remote areas with limited facilities.
One of the limitations of our study is the use of a passive case
detection system, which leaves patients free to visit or not visit
the health facilities when sick. This type of surveillance may miss
some malaria episodes. In addition, patients may visit a different
health facility than that of the study when sick. Because the study
clinics were the most easily accessible health facilities and care
was free of charge for the study children, such events should have
been rare. Some children may also occasionally receive so-called
over-the-counter medication in case of fever. However, treat-
ments delivered outside the health system are not widely avail-
able in the study areas. Despite these issues, it is certain that none
of the children died from or was disabled by malaria, because all
children were followed up after their illness episode.
In conclusion, this study provides solid evidence that the
management strategy for febrile infants in rural outpatient clinics
including a screening for malaria using RDT is feasible and safe
even in infants in a setting of high and moderate endemicity for
both P. falciparum and P. vivax malaria infections. The national
policy in Papua New Guinea has been recently amended to reflect
the new WHO recommendation of laboratory-based diagnosis
and treatment upon result, and our findings provide evidence for
its relevance and safety.
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